This HTML5 document contains 43 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n25http://linked.opendata.cz/resource/drugbank/drug/DB01281/identifier/wikipedia/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/drugbank/drug/DB01281/identifier/pharmgkb/
n19http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n20http://linked.opendata.cz/resource/drugbank/dosage/
n23http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB01281/identifier/kegg-drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01281/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n17http://www.rxlist.com/cgi/generic/
n14http://linked.opendata.cz/resource/drugbank/patent/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01281/identifier/national-drug-code-directory/
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n22http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/atc/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01281
rdf:type
n3:Drug
n3:description
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).
n3:dosage
n20:271B62BD-363D-11E5-9242-09173F13E4C5 n20:271B62BA-363D-11E5-9242-09173F13E4C5 n20:271B62BB-363D-11E5-9242-09173F13E4C5 n20:271B62BC-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dall'Era M, Davis J: CTLA4Ig: a novel inhibitor of costimulation. Lupus. 2004;13(5):372-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15230295 # Moreland L, Bate G, Kirkpatrick P: Abatacept. Nat Rev Drug Discov. 2006 Mar;5(3):185-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16557658 # Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, Nuamah I, Vratsanos G, Zhou Y, Moreland LW: Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol. 2006 Nov;33(11):2162-6. Epub 2006 Oct 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17014006 # Weyand CM, Goronzy JJ: T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006 Apr;2(4):201-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16932686 # Scheinfeld N: Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists. J Dermatolog Treat. 2006;17(4):229-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16971318 # Maxwell LJ, Singh JA: Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol. 2010 Feb;37(2):234-45. Epub 2010 Jan 15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20080922 # Maxwell L, Singh JA: Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007277. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19821401 # Nogid A, Pham DQ: Role of abatacept in the management of rheumatoid arthritis. Clin Ther. 2006 Nov;28(11):1764-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17212998 # Hervey PS, Keam SJ: Abatacept. BioDrugs. 2006;20(1):53-61; discussion 62. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16573350 # Reynolds J, Shojania K, Marra CA: Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis. Pharmacotherapy. 2007 Dec;27(12):1693-701. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18041889 # FDA label
n3:group
approved
n3:halfLife
16.7 (12-23) days in healthy subjects; 13.1 (8-25) days in RA subjects; 14.3 days when subcutaneously administered to adult RA patients.
n3:indication
For the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
owl:sameAs
n5:DB01281 n23:DB01281
dcterms:title
Abatacept
adms:identifier
n7:D03203 n8:0003-2187-10 n9:DB01281 n24:PA164747080 n25:Abatacept
n3:mechanismOfAction
Abatacept is a selective costimulation modulator, like CTLA-4, the drug has shown to inhibit T-cell (T lymphocyte) activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Blockade of this interaction has been shown to inhibit the delivery of the second co-stimulatory signal required for optimal activation of T-cells. This results in the inhibition of autoimmune T-Cell activation that has been implcated in the pathogenesis of rheumatoid arthritis.
n3:packager
n12:271B62B8-363D-11E5-9242-09173F13E4C5 n12:271B62B9-363D-11E5-9242-09173F13E4C5 n12:271B62B7-363D-11E5-9242-09173F13E4C5
n3:patent
n14:2110518
n3:routeOfElimination
kidney and liver
n3:synonym
CTLA4Ig CTLA4IgG4m CTLA4-Ig CTLA4-IgG4m
n3:toxicity
Most common adverse events (≥10%) are headache, upper respiratory tract infection, nasopharyngitis, and nausea. Doses up to 50 mg/kg have been administered without apparent toxic effect.
n3:volumeOfDistribution
* 0.07 L/kg [RA Patients, IV administration] * 0.09 L/kg [Healthy Subjects, IV administration] * 0.11 L/kg [RA patients, subcutaneous administration]
n18:hasAHFSCode
n19:92-00-00
n3:synthesisReference
Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong Il Kim, "Plant Recombinant Human CTLA4IG and a Method for Producing the Same." U.S. Patent US20100189717, issued July 29, 2010.
n15:hasConcept
n16:M0442852
foaf:page
n11:abatacept.html n17:orencia.htm
n3:Molecular-Formula
n22:271B62BF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n22:271B62BE-363D-11E5-9242-09173F13E4C5
n18:hasATCCode
n21:L04AA24
n3:absorption
When a single 10 mg/kg intravenous infusion of abatacept is administered in healthy subjects, the peak plasma concentration (Cmax) was 292 mcg/mL. When multiple doses of 10 mg/kg was given to rheumatoid arthritis (RA) patients, the Cmax was 295 mcg/mL. The bioavailability of abatacept following subcutaneous administration relative to intravenous administration is 78.6%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
332348-12-6
n3:category
n3:clearance
* 0.23 mL/h/kg [Healthy Subjects after 10 mg/kg Intravenous Infusion] * 0.22 mL/h/kg [RA Patients after multiple 10 mg/kg Intravenous Infusions] * 0.4 mL/h/kg [juvenile idiopathic arthritis patients]. The mean systemic clearance is 0.28 mL/h/kg when a subcutaneously administered to adult RA patients. The clearance of abatacept increases with increasing body weight.